Home › Drug Reactions › NCT07216846
The Geriatric Emergency Department Pharmacologic Harm Prevention Project
Who can join
Ages 65 to 110 · All sexes
Full eligibility criteria
Inclusion Criteria: * Patients over the age of 65 with a ground level fall Exclusion Criteria: * hospice and/or DNR status.
About the study
The goal of this project is to determine whether pharmacogenomic testing (using participants' DNA) can help optimize medication prescribing and reduce side effects in older adults taking five or more medications.
The main questions it aims to answer are:
* Can DNA-based prescribing reduce medication-related side effects, especially falls and fall-related injuries? * Does providing pharmacogenomic results to primary care physicians improve medication safety compared with usual care?
Researchers will compare two groups:
1. DNA Care Pathway: Physicians receive patients' DNA results to guide prescribing. 2. Emergency Department Care Pathway: Physicians provide usual care; DNA results are shared only after study completion.
Participants will:
* Provide a cheek swab sample for DNA analysis (1 minute). * Receive monthly follow-up phone calls for 6 months to track falls, injuries, medication changes, and side effects. * Complete a fall and medication calendar. * Allow researchers to review primary care physician medical records for study outcomes.
Approximately 1,000 participants will take part, with follow-up lasting about 6-7 months.
What is being tested
- DNA care pathway (other)
Sponsor: Florida Atlantic University · Participants: 1,000 · Started: Jan 1, 2026
Contact the study team
- Richard Shih, Professor, MD · Phone: 561-737-7733
- Scott Alter, Professor, MD · Phone: 561-737-7733
Official record on ClinicalTrials.gov — NCT07216846
Locations in the U.S.
| Florida | Delray Medical Center, Delray Beach |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.